It has been shown that many MAPK pathway inhibitors, such as the Sprouty family members, the tumor suppressor phosphatase and tensin homolog (PTEN) and Raf kinase inhibitor protein (RKIP) [34–41], are downregulated in prostate cancer cells. This evidence concerns the gene PEBP1 and prostate carcinoma.